FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
Japan lifts ban on lethal arms exports-FT...
The China Show 4/21/2026 (Video)
Broadcom Launches AI-Driven Fraud Detection Product for Payments
Yum! Brands Reports Mixed Short-Term Stock Performance
United Rentals Set to Release Q1 Earnings This Wednesday
Trump Discusses Challenges of Extracting Nuclear Materials from Iran
Magnitude 6 Earthquake Strikes Off Timor Island
RBC trims Ameriprise Financial Inc target price to $560 versus $605 previously....
Apple Asian supplier shares mixed on CEO succession plans
Rigaku shares hit record high on Onto Innovation alliance, stake deal
Morning Bid: Markets long for peace, prepare for Warsh
Oman opens bank in Angola to boost African trade ties
MSCI boots Indonesian tycoon-owned stocks from indices
London Tube Strike Set to Cause Travel Chaos for Commuters
Goldman Sachs Signals Uncertainty for Fed Rate Cuts in 2026
Iran Claims US Attack on Commercial Vessel, Calls for Crew Release
Hong Kong Flight Capacity Set to Rise 10% on China, Korea Demand
Iranian Foreign Ministry: The United States bears full responsibility for the deterioration of the...
Markets Await US-Iran Negotiations Amid Ongoing Strait of Hormuz Closure
John Ternus Named New CEO of Apple
Iranian Foreign Ministry: Iran will employ all its capabilities to defend its interests, national...
Fitch Cuts Philippines’ Rating Outlook as Growth Prospects Dim
Will Iran Let Ships Through In The Strait Of Hormuz? Here's What Prediction Market Is Saying
FirstFT: Apple picks next CEO
Bank of England will only raise rates amid a severe supply shortage
Indonesia’s geophysics agency reports a magnitude 6 quake off Timor Island, with no tsunami...
Jim Cramer Says 'This Is Not A Circular Deal' As Amazon, Anthropic Lock In Massive $100 Billion AI Pact: 'Isn't It Possible That Everyone Wins?'
Trump says efforts to extract nuclear “dust” from Iran will take significant time and be...
U.S. and Iran Engage in Heightened Rhetoric Amid Stalled Peace Talks
JPMorgan’s national security initiative to expand in Europe
Exclusive-SpaceX tries to woo Wall Street with three-day analyst meeting this week, sources say
Iran alleges US struck Iranian commercial vessel, demands crew be released – Foreign...
Kevin Warsh Heads for the Hill: A Confirmation Hearing Guide
It Doesn’t Matter What Kevin Warsh Has to Say
EQT Raises $15.6B for Asia Private Equity Fund
Quilter plc sees JPMorgan reduce its price target to 206p from 212p....
Congo to Halt Cash Dollar Use Next Year to Prop Local Unit
Costco Increases Quarterly Dividend by 13%
AI Stocks Expected to Lead Nasdaq Recovery
Microsoft and Meta Prepare for Earnings Reports Amid AI Competition
IBM Set to Release Earnings Report This Wednesday
Fitch Reports Easing of China's Shadow Lending Practices
South Korea Issues 20-Year Government Bonds at 3.610% Yield
New Zealand’s RBNZ sectoral factor model shows inflation at +2.7% YoY in Q1....
Global clean power growth points to permanent shift, analysts say
The big short meets private credit
EQT and Omers to lift funding for struggling broadband group to €5bn
Seoul shares hit record intraday high on back of tech sector rally-NA...
Toby Neugebauer Incredibly Bullish on Project Matador and Calls for Sale of Company to Maximize Shareholder Value
Amgen Posts 77% Response In Thyroid Eye Disease Study
Amgen Inc. (NASDAQ:AMGN) shares are down on Monday after the company announced topline results from a Phase 3 trial of TEPEZZA, which is administered via an on-body injector for patients with moderate-to-severe active Thyroid Eye Disease.
Trial Meets Primary Endpoint
The Phase 3 TEPEZZA OBI trial met its primary endpoint, showing a statistically significant 77% proptosis (bulging eyes) response rate among participants during the 24-week placebo-controlled period.
The study demonstrated a mean proptosis reduction of -3.17 mm.
Last week, the U.S. Food and Drug Administration (FDA) warned about serious and sometimes fatal liver injuries tied to Amgen’s Tavneos (avacopan)
The agency cited postmarketing data that point to new safety concerns beyond those identified in clinical trials.
Tavneos, approved in October 2021, is used ...
Source: Benzinga